[ad_1]
Medical Targeting Neurotransmitter Systems is unlikely to directly affect the risk of autism Spectrum Disorder (ASD) in seeds, the authors of a study published in JAMA Psychiatry (Online, October 31, 2018) have found[1].
The researchers used data from the Israeli Healthcare System of 1,405 people with ASD and 94,844 controls without an ASD diagnosis, including siblings of those with an ASD diagnosis that were born between January 1997 and December 2007. They are followed by a 11.6-year .
After adjusting for covariates, 5 of 34 medication types are significantly associated with ASD diagnosis, including 4 which are associated with low rates of ASD. Moreover, the researchers found evidence of confounding effects of the number of maternal diagnoses on the union between seeds exposure to medication and ASD.
Maternal diagnoses are therefore more likely to explain the relationship between the medical and the ASD diagnosis in the seeds, they said.
"[The] The diagnostic number of diagnoses can be confused between prenatal exposures and autism, and therefore should be accounted for future studies, "said Magdalena Jainkka of the School of Medicine at Mount Sinai, New York.
Citation: Clinical Pharmacist
You: 10.1211 / CP.2018.20205874
[ad_2]
Source link
